Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
Department of Hepatopancreatobiliary Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830000, China.
Lin
L
Xu
Department of Hepatopancreatobiliary Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830000, China.
Boqing
B
Wang
Department of Hepatopancreatobiliary Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830000, China. Electronic address: xlawxh1015@163.com.
Wei
W
Ding
D000784:Aortic Dissection / Q000139:chemically induced / Q000601:surgery; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017544:Aortic Aneurysm, Abdominal / Q000139:chemically induced / Q000601:surgery; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D057510:Endovascular Procedures / Q000379:methods; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077157:Sorafenib; D015607:Stents; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib